FONTANA, DILETTA

FONTANA, DILETTA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 27 (tempo di esecuzione: 0.01 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 01 - Articolo su rivista 2022 Ramazzotti, DanieleAngaroni, FabrizioMaspero, DavideMauri, MarioD’Aliberti, DeborahFontana, DilettaAntoniotti, MarcoElli, Elena MariaGraudenzi, AlexPiazza, Rocco
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 01 - Articolo su rivista 2021 Fontana, DGambacorti Passerini, CPiazza, R
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma, GGVilla, MMauri, MCrespiatico, IFontana, DMastini, CMagistroni, VCeccon, MRedaelli, SMassimino, LPiazza, RGambacorti Passerini, CMologni, L +
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2021 Fontana D.Gambacorti Passerini C.Piazza R.
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 01 - Articolo su rivista 2020 Nucera, SilviaFazio, GraziaPiazza, RoccoFontana, DilettaGambacorti Passerini, CarloBiondi, AndreaCazzaniga, GiovauniBalduzzi, Adriana +
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 01 - Articolo su rivista 2020 Mori S.Antolini L.Fontana D.Piazza R.Gambacorti Passerini C. +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 01 - Articolo su rivista 2020 Fontana D.Crespiatico I.D'Aliberti D.Massimino L.Bertagna M.Zambrotta G.Bossi M.Fanelli F.Cassina V.Salerno D.Nardo L.Chinello C.Mantegazza F.Magni F.Cavaletti G.Piazza R.Gambacorti-Passerini C. +
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 07 - Tesi di dottorato Bicocca post 2009 2019 FONTANA, DILETTA
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 02 - Intervento a convegno 2019 Diletta FontanaDaniele RamazzottiAndrea AroldiLuca MassiminoElena Maria ElliMonica FumagalliRocco PiazzaCarlo Gambacorti-Passerini +
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 02 - Intervento a convegno 2019 Bossi ESteidl CFontana DSharma GGMologni LPiazza RGGambacorti Passerini C +
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 01 - Articolo su rivista 2019 Magistroni, VMauri, MD'Aliberti, DCrespiatico, IFontana, DSharma, NPirola, ARedaelli, SMassimino, LKhandelwal, PCitterio, SViltadi, MBombelli, SRigolio, RPerego, RGambacorti Passerini, CPiazza, R +
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 02 - Intervento a convegno 2018 Fontana, DMauri, MMassimino, LBossi, MCITTERIO, STEFANIACavaletti, GGambacorti-Passerini, CPiazza, R +
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 01 - Articolo su rivista 2018 Passerini CGFontana D +
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 02 - Intervento a convegno 2018 D. FontanaM. MauriL. MassiminoG. ZambrottaM. BossiS. CitterioG. CavalettiC. Gambacorti-PasseriniR. Piazza +
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 02 - Intervento a convegno 2017 Farina, FCeccon, MMori, SVerga, LBorin, LMMologni, LFontana, DGEETA, GEETAPiazza, RGambacorti-Passerini, C
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 02 - Intervento a convegno 2015 Mologni, LCeccon, MFontana, DPirola, APiazza, RGambacorti-Passerini, C
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 99 - Altro 2015 Ceccon M.Mologni L.Piazza R.Pirola A.Fontana D. +
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 02 - Intervento a convegno 2015 Piazza, RPirola, ADonadoni, CFontana, DRedaelli, SFarina, FGambacorti-Passerini, C +